tick Trading Software AG (FRA:TBX0)

CTI BioPharma Cash Flow Statement

Financials in millions EUR. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Net Income	1.9	1.26	0.89	1.7	5.45	2.01
Depreciation & Amortization	0.21	0.21	0.22	0.22	0.16	0.22
Loss (Gain) From Sale of Assets	-0.01	-0.02	0	-0.01	-0.01	-0.02
Other Operating Activities	-0.21	0.42	-2.21	-1	1.74	0.1
Change in Inventory	-0.3	-0.46	0.44	-0.49	-0	0.07
Change in Accounts Payable	-0.02	-0.07	-0.09	0.25	0.02	-0.08
Change in Other Net Operating Assets	-0.01	0.05	-0.05	-0.22	0.54	0.11
Operating Cash Flow	1.49	1.4	-0.82	0.44	7.9	2.41
Operating Cash Flow Growth	-	-	-	-94.40%	227.19%	-9.91%
Capital Expenditures	-0.14	-0.07	-0.21	-0.45	-0.07	-0.18
Sale of Property, Plant & Equipment	0.03	0.02	-	0.03	0.02	0.04
Sale (Purchase) of Intangibles	-0	-0	-0.04	-0.03	-	-0
Other Investing Activities	0.07	0.07	0.08	0	0	0
Investing Cash Flow	-0.05	0.02	-0.18	-0.45	-0.06	-0.14
Common Dividends Paid	-0.91	-0.91	-1.69	-4.38	-2.02	-1.62
Other Financing Activities	-0	-	-0	-0	-0	-0
Financing Cash Flow	-0.91	-0.91	-1.69	-4.38	-2.02	-1.62
Net Cash Flow	0.53	0.51	-2.69	-4.39	5.82	0.65
Free Cash Flow	1.34	1.33	-1.03	-0	7.82	2.23
Free Cash Flow Growth	-	-	-	-	250.43%	-14.60%
Free Cash Flow Margin	14.81%	15.86%	-12.89%	-0.05%	94.86%	30.47%
Free Cash Flow Per Share	0.67	0.66	-0.51	-0.00	3.88	1.11
Cash Interest Paid	-	-	0	0	0	0
Cash Income Tax Paid	0.52	0.09	2.55	1.19	0.75	0.83
Levered Free Cash Flow	1.44	1.3	-0.84	0.65	3.43	1.69
Unlevered Free Cash Flow	1.44	1.3	-0.84	0.66	3.43	1.69
Change in Net Working Capital	0.33	-0.06	1.57	0.65	-1.54	-0.08

Updated Feb 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.